

**Appendix 2: References and other sources for included studies (part 1 of 3)**

Study identification	References and other sources
29060/785	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_785.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_785.pdf</a>
BRL-29060/874	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_874.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_874.pdf</a>
Derubeis	DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. <i>Arch Gen Psychiatry</i> 2005;62:409-16.
Detke	Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. <i>Eur Neuropsychopharmacol</i> 2004;14:457-70. Unpublished data accessed at <a href="http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4298a.pdf">http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4298a.pdf</a>
Dickens	Dickens C, Jayson M, Sutton C, et al. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. <i>Psychosomatics</i> 2000;41:490-9. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_298.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_298.pdf</a>
Dunbar A	Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. <i>Acta Psychiatr Scand</i> 1993;87:302-5. Claghorn J. A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. <i>Int Clin Psychopharmacol</i> 1992;6(Suppl 4):25-30. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_001.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_001.pdf</a>
Dunbar B	Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. <i>Acta Psychiatr Scand</i> 1993;87:302-5. Claghorn JL. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. <i>J Clin Psychiatry</i> 1992;53(Suppl):33-5. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_002.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_002.pdf</a>
Dunbar C	Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. <i>Acta Psychiatr Scand</i> 1993;87:302-5. Smith WT, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. <i>J Clin Psychiatry</i> 1992;53(Suppl):36-9. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_003.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_02_003.pdf</a>
Dunbar D	Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. <i>Acta Psychiatr Scand</i> 1993;87:302-5. Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. <i>J Clin Psychiatry</i> 1992;53(Suppl):27-9. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR_29060_02_004.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR_29060_02_004.pdf</a>
Dunner	Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. <i>J Clin Psychiatry</i> 1992;53(Suppl):21-6. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_009.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_009.pdf</a>
Edwards	Edwards J, Goldie A. Placebo-controlled trial of paroxetine in depressive illness. <i>Hum Psychopharmacol</i> 1993;8:203-9. Edwards JG, Goldie A, Papayanni-Papasthatis S, et al. The effect of paroxetine on the electroencephalogram, electrocardiogram, and blood pressure. <i>Acta Psychiatr Scand Suppl</i> 1989;350:124. Edwards JG, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. <i>Psychopharmacology (Berl)</i> 1989;97:96-8.
Elliott	Elliott AJ, Uldall KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. <i>Am J Psychiatry</i> 1998;155:367-72. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. <i>Gen Hosp Psychiatry</i> 2002;24:43-7.
F1J-MC-HMAT-SGA	Unpublished data accessed at <a href="http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4091a.pdf">http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4091a.pdf</a>
Feighner A	Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8. Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR03_001.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR03_001.pdf</a>

continued

**Appendix 2: References and other sources for included studies (part 2 of 3)**

Study identification	References and other sources
Feighner B	<p>Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9.</p> <p>Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8.</p> <p>Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_002.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_002.pdf</a></p>
Feighner C	<p>Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9.</p> <p>Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8.</p> <p>Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_003.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_003.pdf</a></p>
Feighner D	<p>Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9.</p> <p>Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8.</p> <p>Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_004.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_004.pdf</a></p>
Feighner E	<p>Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9.</p> <p>Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8.</p> <p>Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_005.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_005.pdf</a></p>
Feighner F	<p>Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine placebo and imipramine in depressed patients. <i>J Affect Disord</i> 1993;28:71-9.</p> <p>Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. <i>Br J Psychiatry</i> 1991;159:394-8.</p> <p>Cohn JB, Wilcox CS. Paroxetine in major depression: a double-blind trial with imipramine and placebo. <i>J Clin Psychiatry</i> 1992;53(Suppl):52-6.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_006.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_006.pdf</a></p>
Golden A	<p>Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. <i>J Clin Psychiatry</i> 2002;63:577-84.</p> <p>Golden RN. Efficacy and tolerability of controlled-release paroxetine. <i>Psychopharmacol Bull</i> 2003;37(Suppl 1):176-86.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_006.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_03_006.pdf</a></p>
Golden B	<p>Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. <i>J Clin Psychiatry</i> 2002;63:577-84.</p> <p>Golden RN. Efficacy and tolerability of controlled-release paroxetine. <i>Psychopharmacol Bull</i> 2003;37(Suppl 1):176-86.</p> <p>Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_449.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_29060_449.pdf</a></p>
Goldstein	<p>Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. <i>J Clin Psychopharmacol</i> 2004;24:389-99.</p> <p>Unpublished data accessed at <a href="http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4091b.pdf">http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4091b.pdf</a></p>
Kramer	<p>Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. <i>Science</i> 1998;281:1640-5.</p> <p>Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. <i>J Clin Psychiatry</i> 2002;63(Suppl 11):25-9.</p>

continued

**Appendix 2: References and other sources for included studies (part 3 of 3)**

Study identification	References and other sources
Loo	Lôo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. <i>Int Clin Psychopharmacol</i> 2002;17:239-47.
MDUK/26090	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MDUK_26090_III_83_007.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MDUK_26090_III_83_007.pdf</a>
Miller	Miller SM, Naylor GJ, Murtagh M, et al. A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. <i>Acta Psychiatr Scand Suppl</i> 1989;350:143-4. Schnyder U, Koller-Leiser A. A double-blind, multicentre study of paroxetine and maprotiline in major depression. <i>Can J Psychiatry</i> 1996;41:239-44. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MDUK_29060_82_006.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MDUK_29060_82_006.pdf</a>
Moller	Moller HJ, Berzowski H, Eckmann F, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. <i>Pharmacopsychiatry</i> 1993;26:75-8 Stuppaek CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. <i>J Clin Psychopharmacol</i> 1994;14:241-6. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_07_001.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR29060_07_001.pdf</a>
Musselman	Musselman DL, Somerset WI, Guo Y, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. <i>J Clin Psychiatry</i> 2006;67:288-96.
MY-1008/BRL	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1008_BRL_076.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1008_BRL_076.pdf</a>
MY-1042/BRL	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1042_BRL_CPMS251.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1042_BRL_CPMS251.pdf</a>
MY-1043/BRL	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1043_BRL_029060_115.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1043_BRL_029060_115.pdf</a>
NKD20006	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_NKD20006.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_NKD20006.pdf</a>
Paile-Hyvarinen	Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. <i>BMC Fam Pract</i> 2003;4:7.
PAR128	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1045_BRL_PAR128.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1045_BRL_PAR128.pdf</a>
PAR279	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_279MDUK_29060_III_83_12.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_279MDUK_29060_III_83_12.pdf</a>
PAR625	Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_625.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR_625.pdf</a>
Perahia	Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. <i>Eur Psychiatry</i> 2006;21:367-78. Unpublished data accessed at <a href="http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4298b.pdf">http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4298b.pdf</a>
Rapaport	Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. <i>J Clin Psychiatry</i> 2003;64:1065-74. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR487.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/III_PAR487.pdf</a>
Rickels	Rickels K, Amsterdam J, Clary C, et al. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. <i>Acta Psychiatr Scand Suppl</i> 1989;350:117-23. Rickels K, Amsterdam J, Clary C, et al. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. <i>J Clin Psychiatry</i> 1992;53(Suppl):30-2. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR_01_001.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/II_PAR_01_001.pdf</a>
Trivedi	Trivedi MH, Pigotti TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. <i>J Clin Psychiatry</i> 2004;65:1356-64. Unpublished data accessed at <a href="http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_810.pdf">http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_810.pdf</a>